BCM
ESPR

Beryl Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Beryl Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14M Buy
+4,431,598
New +$12.4M 12.65% 2

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Beryl Capital Management's ESPR Position: Q2 2026 in Review

Beryl Capital Management opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 4,431,598 shares worth $14M. The stake represents 12.65% of the portfolio and ranks #2 among its holdings.

178 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Beryl Capital Management held 4,431,598 shares of Esperion Therapeutics worth $14M as of Q2 2026.
  • Esperion Therapeutics was a new Beryl Capital Management position in Q2 2026.
  • Esperion Therapeutics made up 12.65% of Beryl Capital Management's portfolio in Q2 2026, its #2 holding.
  • 178 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Beryl Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.